Company intelligence
neuroClues
Expand your neurological assessment with objective, reproducible and quantified eye movement biomarkers.
About neuroClues
In a world where Neurological disorders will affect 1 person in 3 and where the number of parkinson's patient will double in the next decade, reaching 13 million patients. Our mission is to empower clinicians with Biomarkers allowing them to identify Neurological Disorders (Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis) years before visible symptoms. Our ambition with NeuroClues is to become the brain's stethoscope. We are a team of seasoned MedTech entrepreneurs and doctors with as purpose to help our healthcare system cross the chasm of technology with pragmatic solutions. We work from anywhere but our base camps are in Louvain-la-Neuve, Belgium & Paris, France & NY, USA. We’re are looking to connect with individuals, companies, investors and Key Opinion Leaders that share our ambition and mission and that would be willing to partner with us in order to bring NeuroClues to the EU and US market.
Verified activity
Signals from neuroClues
4 published signals
Presence & Recognition
neuroClues celebrated World Physiotherapy Day by highlighting the role of rehabilitation in managing neurological disorders.
Reported by neuroClues
People
neuroClues welcomed Stéphanie Byrnes as its new Clinical Application Specialist.
Reported by neuroClues
People
neuroClues welcomed Joann Sidi Boulenouar as its new Technical Sales Representative for France, with a focus on Western France.
Reported by neuroClues
Presence & Recognition
neuroClues will participate in the European Summer School on Eye Movements at King's College London this September.
Reported by neuroClues